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Background: The interaction between human prostate cancer (PCa) cells and bone marrow (BM) endothelium follows a rolling-
and-adhesion cascade mediated by E-selectin ligand (ESL): E-selectin. This adhesion is enabled by elevated expression of a-1,
3-fucosyltransferases (FTs), enzymes responsible for ESL-mediated bone metastasis in humans. In contrast, the incidence of bone
metastasis in mice is rare.
Methods: FT 3, 6 and 7 were overexpressed in mouse PCa cells. The rolling cell number, cell-rolling velocity and transendothelial
migration were characterised in vitro. Fucosyltransferases-transduced mouse PCa cells expressing luciferase were inoculated into
mice via left ventricle to compare the capability of bone metastasis. Mass spectrometry and immunoprecipitation were utilised for
identification of ESLs.
Results: Overexpression of FT3, FT6 or FT7 restored ESLs and enabled mouse PCa cells to roll and adhere in E-selectin-
functionalised microtubes, similar to trafficking of circulating PCa cells in BM vessels. Following intracardiac inoculation,
FT6-transduced cells induced robust bone metastasis in mice. Inhibition of FT6 by a fucose mimetic significantly reduced bone
metastasis. Importantly, comparison of FT3, FT6 and FT7 gene expression in existing clinical samples showed significant
upregulation of FT6 in PCa-distant metastases.
Conclusion: FT6 is a key mediator of PCa cells trafficking to the BM. It may serve as a viable drug target in preclinical tests of
therapeutics for reduction of PCa bone metastasis.
Prostate cancer (PCa) is the leading cause of cancer death among
American men, second only to lung cancer in 2012. When detected
at an early stage, the 5-year survival rate is close to 100%.
In contrast, if diagnosed at a late stage with advanced metastatic
disease, the 5-year survival decreases to 33% (Siegel et al, 2012).
The most common metastatic sites of PCa are lymph nodes, bones,
lung and liver (Wilt and Ahmed, 2013). Among these sites, bone is
the most challenging organ for therapeutic intervention as bone
metastasis can cause severe skeleton-related diseases such as bone
pain, hypercalcemia, fractures and nerve compression syndromes
(Saad et al, 2006; Sturge et al, 2011).
Metastasis to bone is a multistep cascade. Prostate cancer
cells detached from the primary site must first invade a blood
vessel, a process called intravasation. Through hematogenous
dissemination, a sub-population of cells attach to bone marrow
(BM) endothelial cells. This process is mediated by multiple
receptor–ligand interactions under shear stress, referred to as a
rolling-and-adhesion cascade (Li and King, 2012). This cascade
further facilitates PCa cells to breach the bone endothelial layer
(transendothelial migration; TEM) to establish micrometastases in
the bone microenvironment (Barthel et al, 2013).
Bone marrow endothelial cells constitutively express E-selectin,
which enables homing of hematopoietic stem cells expressing
E-selectin ligands (ESLs) to the BM (Sackstein, 2012; Winkler et al,
2012). Recent studies have indicated that human PCa cells also
express similar ESLs to interact and traverse the vasculature of the
BM (Dimitroff et al, 2004, 2005; Barthel et al, 2013). E-selectin
ligands comprise the tetrasaccharide sialyl Lewis X (sLe
x) attached
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The synthesis of sLe
x on such glycoproteins is catalysed in the
Golgi compartment by members of the glycosyltransferase
gene family. The final step involves the transfer of fucose to
N-acetylglucosamine at the terminal a-2, 3 sialo-lactosamine unit
by a-1, 3-fucosyltransferases (FT) 3, 4, 5, 6 and/or 7 depending on
the cell type (de Vries et al, 2001). Gene expression profiling and
immunohistology in several human PCa cell lines have shown that
the bone metastasis potential correlates well with the expression
level of FTs (Barthel et al, 2008; Yin et al, 2010). To the contrary,
the rare evidence of bone metastasis in mice genetically prone to
PCa raises the question of whether mouse PCa cells express ESLs
(Gingrich et al, 1996). Moreover, if they are absent in mouse PCa
cells, can one develop a new mouse model with robust bone
metastasis by increasing expression of functional ESLs?
MATERIALS AND METHODS
Cell lines and mice. The transgenic adenocarcinoma of the mouse
prostate (TRAMP) cell lines TRAMP-C1 and TRAMP-C2 were
obtained from American Type Culture Collection (ATCC; Rock-
ville, MD, USA) and cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen, Grand Island, NY, USA) with 4mM
L-glutamine adjusted to contain 1.5gl
 1 sodium bicarbonate and
4.5gl
 1 glucose supplemented with 0.005mgml
 1 bovine insulin
and 10nM dehydroisoandrosterone, 90%; fetal bovine serum (BD
Biosciences, San Jose, CA, USA), 5%; Nu-Serum IV (BD
Biosciences), 5%. RM1 cells are a murine- androgen-insensitive
PCa cell line, which were kindly provided by T Thompson (MD
Anderson Cancer Center, Houston, TX, USA) for this study. RM1
cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS. Human umbilical vein endothelial
cells (HUVEC) were obtained from ATCC and cultured in vascular
cell basal medium (ATCC) using the endothelial cell growth kit-
BBE (ATCC PCS-100-040). Human umbilical vein endothelial cells
were used up to passage number 6. Six- to 8-week-old male C57BL/6
mice were purchased from Jackson Laboratory (Bar Harbor, ME,
USA). Mice were housed in a SPF barrier animal facility at the
Cornell University.
Antibodies. The following recombinant proteins or antibodies
were employed to characterise ESLs in this study: recombinant
mouse E-selectin/CD62E Fc chimera (R&D Systems, Minneapolis,
MN, USA), PE goat anti-human IgG (Santa Cruz Biotech,
Santa Cruz, CA, USA), FITC HECA-452 (BD Biosciences), PE
anti-mouse PSGL-1 (BD Biosciences) and FITC anti-mouse CD44
(BD Biosciences). The following antibodies from BD Biosciences
were used as isotype controls: FITC Rat IgG2b, FITC Rat IgM and
PE Rat IgG1.
Flow cytometry. Cells were detached with enzyme-free Gibco Cell
Dissociation Buffer (Invitrogen) and suspended at a concentration
of 5 10
5 cells in 100ml cold PBS/1% bovine serum albumin
(BSA). Primary antibodies or corresponding isotype control
antibodies were incubated with cells for 30min on ice. Following
two washes with 1ml PBS/1% BSA, fluorescence measurements
were collected on an Accuri C6 flow cytometer (BD Biosciences).
Data were analysed using the Flow Express software (De Novo
Software, Los Angeles, CA, USA). Cells were gated based on
forward and side scatter. For detection of ESLs, recombinant
mouse E-selectin/CD62E Fc chimera was used at a concentration
of 10mgml
 1. Cells were suspended at a concentration of 5 10
5
cells in 100ml cold binding buffer PBS/1% BSA/2mM Ca
2þ or
control buffer PBS/1% BSA/1mM EDTA. Incubation was per-
formed for 30min on ice. Cells were washed with binding buffer or
control buffer twice and stained with secondary PE anti-human
IgG for 30min on ice.
Western blotting and immunoprecipitation. For western
blotting, whole-cell lysates were prepared and separated by 8%
SDS–PAGE as previously described (Bu et al, 2013). Membranes
were incubated with primary antibodies HECA-452 (BD
Biosciences), anti-b actin (Santa Cruz Biotech) and recombinant
mouse E-selectin-Fc (R&D Systems). All primary antibodies were
diluted 1:1000. Mouse E-selectin-Fc was diluted to 1mgml
 1 in
the presence of 2.5mM CaCI2. Immunoprecipitation was per-
formed to identify E-selectin-reactive membrane protein as
previously described (Matsumoto et al, 2005). Five hundred
micrograms of precleared proteins were incubated with either
5mg human IgG isotype or 5mg mouse E-selectin-Fc. The prepared
samples were separated and analysed by western blotting.
Anti-CD44 (Biolegend, San Diego, CA, USA) was used at
1:1000 dilution in the blotting.
Identification of E-selectin-Fc-reactive protein by mass
spectrometry. Lysates from empty vector- and FT6-transduced
TRAMP-C2 were subjected to immunoprecipitation by
E-selectin-Fc. Proteins that interacted with E-selectin-Fc were
analysed by 8% SDS–PAGE. To guide localisation, excision and
retention of the relevant protein, an E-selectin-Fc-immunostained
blot was prepared from the same gel. The stained blot was
superimposed with the corresponding gel to excise the fragment in
the gel. The fragment was digested with trypsin and analysed by
nano HPLC MS/MS with Orbitrap Elite (Thermo Fisher Scientific
Inc., Waltham, MA, USA), and the NCBI database was searched
for possible peptide matches. The peptide sequences from empty
vector-transduced samples were used as background control to
exclude non-specific interaction with E-selectin-Fc.
Retroviral production and transduction. Retroviral vectors
encoding human a-1,3 FT3, FT6, FT7 and retrovirus packaging
helper plasmids pN8e-gag_pol_deltaS and pN8e-VSV-G were
utilised. Briefly, retroviral vectors and two helper plasmids were
transfected into HEK293T cells by TransIT-LT1 Transfection
Reagent (Mirus Biology, Madison, WI, USA). Virus supernatants
were collected at 48 and 72h after transfection. Virus supernatants
were mixed with target cells in the presence of 8mgml
 1
polybrene (Santa Cruz Biotech) for 24h. Afterwards, fresh media
was added and cells were selected with 200mgml
 1 G418
for 2 weeks.
Tumour cell TEM assay. The QCM Tumor Cell Transendothelial
Migration Assay kit (Millipore, Billerica, MA, USA) was used in
this study. Briefly, 1 10
5 endothelial cells in 250ml endothelial
cell culture medium were loaded into each insert. After cells grew
to 495% confluence, endothelial cell monolayers were activated
with 20ngml
 1 of recombinant human TNF-a for 4h. Tumour
cells (1 10
5) were suspended in 250ml serum-free media and
loaded into the insert. Tumour cells were allowed to migrate for
24h at 371C. Cells that migrated to the bottom of the inserts were
fixed with 100% methanol, stained with crystal violet and counted
on a microscope.
Preparation of E-selectin-functionalized microtube and rolling
experiments. Fifty centimetre-long microrenathane microtubes
with 300mm inner diameter (Braintree Scientific, Braintree, MA,
USA) were first washed with 1  PBS and then coated with
10mgml
 1 of recombinant protein G (Calbiochem, Frankfurt,
Germany) for 1h at room temperature. Microtubes were incubated
with 0.125mgml
 1 of recombinant mouse E-selectin/Fc chimera
for 2h. The surface was then blocked with 5% fat-free milk for
0.5h to avoid non-specific interaction of cells with the tube surface.
Tubes were washed with PBS
þþ (PBS saturated with calcium
chloride; Invitrogen) and dissociated monolayer cells at a
concentration of 1 10
6cells per ml in PBS
þþ were perfused
through at 2dyncm
 2 using a syringe pump (IITC Life Sciences,
Woodland Hills, CA, USA). Functionalized microtubes were
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microscope (Olympus America, Melville, NY, USA). A CCD
camera (Hitachi, Tokyo, Japan) and DVD recorder (Sony
Electronics, Tokyo, Japan) were used to record experiments.
Videos were later analysed using in-house ImageJ (NIH, Bethesda,
MA, USA) stack tools to quantify rolling velocities. The number of
cells per frame of rolling video was manually counted.
Animal studies. All mice were handled according to the Guide for
the Care and Use of Laboratory Animals in compliance with UK-
based guidelines. All experimental procedures and protocols were
approved by the Institutional Animal Care and Use Committee of
Cornell University (Protocol number 2011-0051). Male C57BL/6
mice (age 6–8 weeks) were anaesthetised by 2.5% isoflurane on the
day of injections. On day 0, anaesthetised animals were injected
with 1 10
5 cells suspended in 100ml sterile DPBS containing
300mg/ml D-luciferin into the left ventricle of the heart by non-
surgical means via a 29G needle (BD Biosciences). After injection,
mice were subject to bioluminescence imaging (BLI).
Bioluminescence imaging. Bioluminescence imaging was per-
formed with a CCD camera mounted in a light-tight specimen box
(Xenogen, Waltham, MA, USA). Imaging and quantification of
signals were controlled by the acquisition and analysis software
Living Image (Xenogen). Anaesthetised mice were placed in the
IVIS Imaging System and imaged from ventral views B10–15min
after intraperitoneal injection of D-luciferin at 150mgkg
 1 body
weight. For experiments on day 0, successful intracardiac injections
were indicated by images showing systemic bioluminescence
distributed throughout the animal. Only mice with evidence of a
satisfactory injection continued in the experiments. Assessment of
subsequent metastasis was monitored in vivo after 1 week.
Histology. Mouse hind legs were fixed in 4% formaldehyde in PBS
overnight and then decalcified in 10% formic acid in 10% formalin/
PBS overnight. Decalcified hind legs were embedded in paraffin
after tissue processing (dehydration, clearance and impregnation).
Serial sections (5mm) from each tissue block were cut onto slides
and every fifth section was stained with hematoxylin and eosin
(H&E) as previously described (Granot et al, 2011). Hematoxylin
and eosin-stained slides were imaged with an upright Olympus
BX-50 microscope equipped with a Moticam 2300 colour camera
(Cole-Parmer, Vernon Hills, IL, USA).
Statistical analysis. All statistical analyses were performed using
GraphPad Prism 5.0a for Mac OS X (San Diego, CA, USA). One-
way ANOVA followed by Tukey’s post test was used to compare
statistical significance in the characterisation of rolling velocity,
number of rolling cells, TEM and quantification of biolumines-
cence signals. When analysing gene expression of FTs in the NCBI
database, significance was calculated by Student’s t-test.
RESULTS
Mouse PCa cells do not express ESLs. E-selectin is a transmem-
brane glycoprotein that binds ESLs through its extracellular
domain in a Ca
2þ-dependent manner (Graves et al, 1994). Three
representative mouse PCa cell lines (TRAMP-C1, TRAMP-C2 and
RM1) were examined in this study. TRAMP-C1 and TRAMP-C2
were derived from the TRAMP mouse (Foster et al, 1997). This
model was generated by overexpressing SV40, which suppresses
p53 and Rb to mimic loss of function in tumour suppressor genes.
In contrast, the RM1 cell line was developed from the
mouse prostate reconstitution model (Thompson et al, 1989).
This model overexpresses the oncogene Ras. To test their binding
to mouse E-selectin, cells were incubated with dimerised
E-selectin-human IgG Fc chimera and fluorescently labelled
anti-human Fc. This measurement showed that all three cell lines
express low level of ESLs (Figure 1A).
Mouse PCa cells express certain glycoprotein ESLs but not
sLe
x. The glycoproteins PSGL-1 and CD44 have been identified as
ESLs in human PCa, colon cancer and breast cancer (Dimitroff
et al, 2005; Burdick et al, 2006; Zen et al, 2008). It is not clear
whether the lack of functional ESLs is because of the absence of
similar glycoproteins or a lack of sLe
x in mouse PCa cells
(Figure 1B). Antibodies recognising mouse PSGL-1 and CD44 were
applied to TRAMP-C1, TRAMP-C2 and RM1 cells. None of them
were found to express PSGL-1; however, CD44 is present on the
cell surface of all three cell lines (Figure 1C). These glycoproteins
serve as scaffolds to present the tetrasaccharide sLe
x, which can
directly interact with E-selectin. Using an antibody that recognises
sLe
x (HECA-452), it was found that none of these mouse PCa cell
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Figure 1. Characterisation of ESLs in mouse PCa cells. (A) Mouse PCa
cells have low binding affinity to E-selectin. TRAMP-C1, TRAMP-C2 and
RM1 were assayed for mouse E-selectin-Fc chimera binding. Staining
was performed in the presence of 2mM Ca
2þ (red histograms) or 1mM
EDTA (black histograms); n¼3. Representative histograms from three
experiments are shown. (B) A cartoon showing components of ESLs
required for the binding of ESLs to E-selectin. (C) Mouse PCa cells
express ESL scaffold but lack essential carbohydrate. Mouse PSGL-1,
CD44 and sLe
x were assayed with PE-anti-PSGL-1, FITC-anti-CD44 and
FITC-HECA-452 antibodies (red histograms) or corresponding isotypes
(black histograms); n¼3. Representative histograms from three
experiments are shown.
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x (Figure 1C). Although previous work suggests
that mouse ESLs are not recognised by the HECA-452 antibody
because of differences in sialic-acid composition compared with
human ESLs (Mitoma et al, 2009), it was found in the present
study that the introduction of fucose by overexpression of a-1,3
FTs restored the binding of HECA-452 to mouse cell lines. This
validates the use of HECA-452 to identify sLe
x in this work
(Supplementary Figure 1). Thus, we may conclude that the lack of
sLe
x is likely responsible for the deficiency in E-selectin binding.
FT3, FT6 and FT7 induce functional ESL expression on mouse
PCa cells. The final step of sLe
x synthesis on glycoproteins
involves the transfer of fucose to N-acetylglucosamine catalysed by
a-1,3-FT. The upregulation of a-1,3 FT3, 6 and 7 in human
metastatic PCa tissues motivates the examination of whether FT3,
FT6, or FT7 could be involved directly in the expression of sLe
x in
mouse PCa cell lines (Barthel et al, 2008, 2009). cDNA-encoding
human FT3, FT6 and FT7 were packaged into retroviral particles
and transduced into the TRAMP-C1, TRAMP-C2 and RM1 cell
lines to establish stable cell clones. Indeed, overexpression of FT3,
FT6 or FT7 restored E-selectin-binding in mouse PCa cells
compared with empty vector-transduced cell lines (Figure 2). Thus,
overexpression of FTs completes the final step of sLe
x synthesis
and enables E-selectin binding in mouse PCa cells.
Characterisation of rolling behaviour of FT-transduced cells.
We next examined E-selectin binding in a dynamic fluid flow
system. A previously established flow-based microtube system was
employed to mimic the bone microvascular environment
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Figure 3. a-1,3-Fucosyltransferases mediate robust but distinct mouse PCa cell rolling in E-selectin-coated microtubes. (A) A cartoon of a
biomimetic microtube is shown. The inner surface of microtubes were functionalized with protein G and E-selectin-Fc chimera to mimic constitutive
E-selectin expression on BM endothelial cells. (B) Cell-rolling velocity for a-1,3-FT-transduced TRAMP-C1, TRAMP-C2 and RM1, respectively.
Thirty rolling cells were recorded under physiological WSS of 2dyncm
 2 from each independent experiment. ‘No rolling’ indicates that empty
vector-transfected cells failed to roll on E-selectin surfaces. Results are the mean±s.e.m. of three experiments; **Po0.01, ***Po0.001.
(C) Number of rolling cells interacting with E-selectin-functionalized surfaces per frame under physiological WSS of 2dyncm
 2. Ten frames
were recorded for each experiment. Results are the mean±s.e.m. of three experiments; **Po0.01, ***Po0.001.
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Figure 2. a-1,3-Fucosyltransferases are potent inducers of E-selectin
binding in mouse PCa cells. Retrovirus packaged with empty vector
(vehicle control), FT3, FT6 and FT7 were transduced into TRAMP-C1,
TRAMP-C2 and RM1 cells. Stable cells were established under
selection with G418 (400mgml
 1) for 2 weeks. Afterwards, cells were
assayed for mouse E-selectin-Fc chimera binding. Staining in the
presence of 2mM Ca
2þ (red histograms) or 1mM EDTA (black
histograms); n¼2. Representative histograms from two experiments
are shown.
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Results are the mean±s.e.m. of three experiments; ***Po0.001.
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Figure 5. FT6 induces the highest incidence of bone metastasis using TRAMP-C2 cells in C57BL/6 mice. (A) A cartoon illustrating the procedures
including intracardiac injection and BLI is shown. (B) Quantification of bone metastases in femurs and tibias 1 week after inoculation of PCa cells.
BLI signals collected on day 7 were normalised to whole-body BLI on day 0. FT6-induced statistically significant bone metastasis compared
with empty vector, FT3 and FT7 groups. For each group, n¼6. The experiment was repeated twice; results are mean±s.e.m. from two
independent experiments; *Po0.05, **Po0.01. (C) Representative BLI images taken 1 week after PCa inoculation. Heat bar is represented as
counts. Bioluminescence imaging signalso600 counts were considered noise and removed per manufacturer’s suggestion. (D) Representative
images of H&E staining from BLI-positive areas. Bioluminescence imaging was found to come largely from femurs proximal to knee joints.
Abbreviations: BM¼bone marrow, T¼tumour.
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Briefly, the inner surface of microtubes were coated with mouse
E-selectin-Fc chimera (Figure 3A). To simulate circulating
behaviour, PCa cells were perfused at physiological wall shear
stress (WSS) through the microtube lumen, and their rolling
behaviour was characterised by measuring the rolling velocity and
recording the number of interacting cells. In all three cell lines,
FT6-transduced cells exhibited the slowest rolling velocity under
physiological WSS of 2dyncm
 2 (Figure 3B). The rolling
adhesion was Ca
2þ dependent, as flushing with 1mM EDTA
abolished cell binding as expected for E-selectin adhesion (data not
shown). In contrast, cells transduced with empty vector were
unable to roll or interact with E-selectin-coated microtubes
(Figure 3B). In addition, FT6-overexpressing cells displayed the
highest number of rolling cells interacting with E-selectin-coated
surfaces (Figure 3C, Supplementary Figure 2). The behaviour in
this biomimetic in vitro system suggests that ESLs may support the
recruitment of CTCs from circulation to the bone endothelium
in vivo.
TEM of FT-transduced cells. After CTCs roll and form firm
adhesions with the endothelial layer in BM microvessels, CTCs
must breach this layer to establish micrometastases, a process
referred to as TEM. To assess TEM capability, empty vector or
FT-transduced TRAMP-C1, TRAMP-C2 and RM1 cells were
seeded on confluent monolayers of endothelial cells pre-stimulated
with TNF-a to transiently express E-selectin. The potential of TEM
was measured by counting cells that migrated through the layer
after 24h incubation (Figure 4A). Notably, FT6-transduced
cells showed greater TEM ability than empty vector, FT3- and
FT7-transduced cells (Figures 4B–D, Supplementary Figure 3).
FT6 promotes the greatest potential for BM metastasis. We next
investigated whether the differential rolling velocity and TEM are
sufficient to lead to distinct BM metastases in immune-competent
mice. Equal numbers of empty vector or FT-transduced TRAMP-
C2 cells stably expressing firefly luciferase were injected into the
left ventricle of C57BL/6 mice. The intracardiac route was selected
to allow for systemic dissemination of CTCs before becoming
entrapped in the microvessels of the lung (Campbell et al, 2012;
Zou et al, 2013). One week after cell injection, bone metastases
were quantified by measuring luminescence signal in the tibia and
femur (Figure 5A). The bioluminescence signal from the tibias and
femurs were normalised to whole-body luminescence signal taken
on day 0. Consistent with the in vitro findings, FT6-transduced
TRAMP-C2 cells developed the highest metastatic burden in the
bone (Figures 5B and C). Further examination of BM invasion by
H&E staining revealed that only FT6-transduced TRAMP-C2 cells
established significant metastases in the femur proximal to the
knee joint (Figure 5D).
FT6 converts CD44 to a functional ESL. To identify candidate
ESLs induced by the overexpression of FTs, the glycoproteins from
total lysates of FT-transduced TRAMP-C2 cells were examined by
western blotting. Both mouse E-selectin-Fc and HECA-452
identified protein bands of a similar size, indicating that the ESLs
formed after overexpression of FTs are positive for sLe
x- or sLe
x-
like glycan (Figure 6A). Whereas FT3-transduced cells were not
detectable by either E-selectin-Fc or HECA-452, FT6 and FT7
generated unique patterns of ESLs in the blots. It is possible that
FT3-induced ESLs are primarily glycolipids or glycoproteins
that cannot be readily detected because of the denaturation step
of western blotting. Noting that the slowest rolling velocity and
greatest TEM found in vitro as well as the highest incidence
of bone metastasis in vivo was observed for FT6, the identity of
unique glycoproteins was further investigated in FT6-transduced
TRAMP-C2. The distinct fragment produced by FT6 lysate was
excised from SDS–PAGE gel after superimposition to the band
of a similar size in blots and analysed by mass spectrometry.
An E-selectin-binding, sLe
x-bearing protein, CD44, was identified
and further validated through immunoprecipitation by beads
conjugated to E-selectin-Fc (Figure 6B). Consistent with human
studies, CD44 has been found to be a key protein that is involved in
the adherence of metastatic prostate and breast cancer cells to BM
endothelial cells (Draffin et al, 2004).
FT6 expression correlates with clinical PCa progression. To
access the clinical relevance of FT6 in human PCa, the gene
expression profile of FT6 was analysed through public microarray
repositories from the NCBI Gene Expression Omnibus (profile
number GDS2545, Metastatic PCa HG-U95A). It consists of three
categories: (1) normal prostate tissue adjacent to PCa tumour
(n¼63), (2) primary PCa tumours (n¼65) and (3) distant
metastasis samples (n¼25). We found higher levels of FT6 in
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Figure 6. CD44 is a primary ESL following FT6 overexpression.
(A) Western blotting of membrane proteins from FT3-, FT6- and
FT7-transduced TRAMP-C2 cells. Distinct patterns were identified after
proteins were probed with E-selectin-Fc and anti-sLe
x mAb HECA-452.
Empty vector-transduced TRAMP-C2 served as a background control.
Anti-b actin was used as a loading control. (B) E-selectin-Fc
immunoprecipitates from FTs-transduced TRAMP-C2 proteins were
subjected to western blotting and immunostained with anti-CD44.
Human IgG immunoprecipitates were not reactive with anti-CD44
indicating specific interaction between E-selectin and CD44. Only FT6
cells generated a CD44-reactive band showing that FT3 and FT7 were
unable to modify CD44 to become a functional ESL.
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www.bjcancer.com|DOI:10.1038/bjc.2013.690 3019primary prostate tumours (P¼0.05) and metastatic tumours
(P¼0.001) in comparison with normal prostate epithelium
adjacent to primary PCa tumours (Figure 7B, Supplementary
Table). No significant difference was found when examining
FT3 and FT7 in the same tissues, except for an increase in FT3
expression in distant metastasis samples compared with normal
prostate epithelium adjacent to tumours (P¼0.04; Figure 7A and C,
Supplementary Table).
a-1, 3-FT inhibitor reduces FT6-dependent bone metastasis.
The in vivo experiments in this work along with gene expression
profiles from clinical samples support the idea that FT6 may be one
of the key mediators that drives bone metastasis. Thus, it is of
therapeutic interest to explore whether the inhibition of FT6
can reduce bone metastasis in our mouse model. To this end,
fluorinated fucose mimetic (2F-peracetyl-fucose) was utilised
to inhibit the activity of FT6 (Figure 8A). Following 3 days of
incubation with 20mgml
 1 2F-peracetyl-fucose, FT6-transduced
TRAMP-C2 showed reduced E-selectin binding (Figure 8B). This
concentration did not compromise cell viability (data not shown),
consistent with a prior study in which a three-fold higher
concentration did not affect the viability of leukocytes
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Figure 8. Inhibition of FT6 by fucose mimetic (2F-peracetyl-fucose) reduces bone metastasis. (A) Molecular structure of 2F-peracetyl-fucose and
natural fucose. (B) Fucosyltransferase 6-transduced TRAMP-C2 cells were treated with 20mgml
 1 2F-peracetyl-fucose or 0.2% DMSO for 96h. The
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metastasis in vivo. Fucosyltransferase 6-transduced TRAMP-C2 cells with the same treatment as (B) were injected into the left ventricle of C57BL/6 mice.
Bone metastases in femurs and tibias were quantified by BLI 1 week later. Significance was analysed by Student’s t-test. DMSO group, n¼5. 2F-
peracetyl-fucose group, n¼4. (D) Representative image of bone metastases in study (C). Arrows indicate areas of bone metastases.
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in vivo, FT6-transduced TRAMP-C2 cells that received the same
treatment or vesicle control (DMSO) were injected into C57BL/6
mice via the left ventricle. One week later, fucose mimetic-treated
cells produced significantly fewer and smaller bone metastases
compared with DMSO treatment quantified by BLI (Figure 8C and
D). As 2F-peracetyl-fucose is highly cell permeable and has not
been shown to reduce cell viability in prior studies, we reason that
it represents a potential therapeutic for the reduction of bone
metastasis.
DISCUSSION
In this work, we aimed to dissect the molecular mechanism of why
bone metastasis is a frequent occurrence in the human disease but
rare in mouse. Our results indicated that the lack of functional
ESLs in mouse cell lines may partly explain this discrepancy.
As ESLs are composed of a scaffold protein or lipid decorated by
the tetrasaccride sLe
x, we further identified a lack of sLe
x in mouse
PCa cells. However, overexpression of human a-1,3 FTs in mouse
PCa cells restored E-selectin binding and led to the rolling of PCa
cells in E-selectin-coated microtubes under physiological flow
conditions. Interestingly, the different FTs (FT3, FT6 and FT7)
showed differential rolling velocities and TEM capability in vitro.
Among the three mouse PCa cell lines tested (TRAMP-C1,
TRAMP-C2 and RM1), FT6-transduced cells showed the slowest
rolling velocity and the highest degree of TEM. To correlate these
in vitro findings with in vivo metastatic potential, we inoculated
FT-transduced TRAMP-C2 cells labelled with firefly luciferase
into the left ventricle of wild-type C57BL/6 mice. Within 1 week,
the FT6-overexpressing cells promoted significant bone metastasis
in the tibia and femur as detected by BLI. We further identified
CD44 as a primary ESL in cells expressing FT6 but not FT3 or FT7.
This correlates with previous studies in human cells where CD44
promoted the adherence of metastatic cancer cells and mesen-
chymal stem cells to BM endothelial cells (Draffin et al, 2004;
Burdick et al, 2006; Sackstein et al, 2007; Zen et al, 2008;
Sackstein, 2012).
Interestingly, previous work by the Dimitroff lab showed that
FT7 rather than FT3 or FT6 promoted trafficking of human PC3
PCa cells to immunodeficient mouse BM (Barthel et al, 2009). This
may reflect inherent species-dependent differences between mouse
and human-derived PCa cells. It should be noted that the mouse
genome does not include the FT3 or FT6 genes and only FT4 and
FT7 are inherently present to support E-selectin-mediated
leukocyte rolling (Weninger et al, 2000; Homeister et al, 2001).
Expression of human FT6 in mouse PCa cells may compensate for
this loss during evolution. Despite such interspecies differences,
FT6 has been found to be elevated in other human bone metastatic
PCa and breast cancer cell lines (Matsuura et al, 1998; Barthel et al,
2008). Moreover, one of significant findings in this work is that
FT6 gene expression correlates best to clinical PCa progression and
metastasis as revealed by public microarray repositories from the
NCBI Gene Expression Omnibus.
Previous study in breast cancer indicates that ESLs mediate
breast cancer cell TEM and that E-selectin-blocking antibody can
functionally abolish this migration in vitro (Zen et al, 2008).
Although it is not clear whether FT has a role in the TEM of breast
cancer cells, it was shown that ESLs prime TEM of human
mesenchymal stromal cells (MSCs) and direct them to bone by
maintaining ESL expression in MSCs via FT6 (Sackstein et al, 2007,
2008; Thankamony and Sackstein, 2011). Viewing this previous
work in light of the current study, we speculate that therapeutic
targeting of ESLs could prevent both E-selectin-mediated traffick-
ing to bone and TEM in the reduction of PCa bone metastasis.
Many cancers have been found to associate with inflammation
as exemplified by the infiltration of tumour-associated macro-
phages and regulator T cells, and inflammation can further
aggravate cancer progression (Grivennikov et al, 2010). In this
study, we utilised the fucose mimetic 2F-peracetyl-fucose to inhibit
FT enzyme activity and achieved a significant reduction of bone
metastasis in the FT6-induced bone metastasis mouse model.
This inhibitor along with other sugar mimetics have been
suggested to suppress inflammation by inhibiting the synthesis of
ESLs in infiltrating leukocytes without affecting cell viability
(Barthel et al, 2011; Rillahan et al, 2012). We suggest that fucose
mimetics may be potential drugs that target the vicious cycle of
inflammation and cancer progression. In addition to these sugar
inhibitors, siRNA that targets specific FTs can also be utilised
(Yin et al, 2010).
This newly developed experimental metastasis model has several
advantages over existing mouse models of bone metastasis: (1) It
bypasses complicated surgical implantation of PCa cells in the bone.
Moreover, the direct intraosseous implantation bypasses several
crucial steps in the metastatic cascade: survival in the bloodstream,
rolling and extravasation (McCabe et al, 2008); (2) Is less time
consuming than iterative selection of the bone metastatic PCa cells
(Power et al, 2009); (3) the use of wild-type mouse allows for the
study of PCa development in an immunocompetent background,
which considers the involvement of the immune system.
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